Pop Test gets patent for glucose measuring device
CLIFFSIDE PARK, N.J. The U.S. Patent and Trademark Office has granted a patent to the privately owned company Pop Test for a means for diabetics to measure their glucose levels without drawing blood, Pop Test said Tuesday.
The company said it is conducting clinical trials on a glucose test that uses saliva to allow Type 1 and Type 2 diabetes patients to monitor blood glucose, and can detect abnormally low and abnormally high blood sugar levels.
The company also is developing tests for cholesterol, stress, drugs and alcohol, and pregnancy.
“The Pop Test device will be a tremendous benefit to the millions of people who are afflicted with diabetes around the world,” Pop Test founder Randi Altschul said. “Consumers will be able to monitor their health condition at home with a simple, affordable and painless self-testing device that uses saliva reliably instead of blood.”
CVS/pharmacy, Warner Home Video support the Cystic Fibrosis Foundation
BETHESDA, Md. The Cystic Fibrosis Foundation announced on Monday that it will partner with CVS/pharmacy and Warner Home Video for the second year to raise funds for cystic fibrosis through the sale of classic family movies this holiday season.
From now through Dec. 28, CVS/pharmacy will sell four animated holiday movies from Warner Home Video, including “How the Grinch Stole Christmas,” “The Year Without a Santa Claus,” “Charlie Brown’s Christmas Tales” and “The Polar Express.” The videos will be sold exclusively at CVS/pharmacy. For every video purchased, CVS/pharmacy and Warner Home Video will donate $5 to benefit the Foundation.
Cystic fibrosis is a fatal genetic disease that causes life-threatening lung infections and premature death. It affects about 70,000 people worldwide. The foundation has fueled dramatic improvements in research and care that have changed the prognosis for people with the disease. Where most children with cystic fibrosis once died before reaching elementary school, now people with the disease live into their 30s and beyond.
RA patients may benefit from weekly injection of Orencia, study finds
NEW YORK Patients with rheumatoid arthritis derive about as much benefit from a weekly injection of a biotech drug made by Bristol-Myers Squibb for the disease as they do from receiving it via IV on a monthly basis, according to late-stage clinical trial data released Monday.
Bristol announced results of a phase-3 study showing that patients with moderate to severe RA receiving a weekly injection under the skin of Orencia (abatacept) showed similar improvements to those receiving the IV. Results of the study will be presented this week at the American College of Rheumatology’s annual scientific meeting in Atlanta.
The study included 1,457 patients who had moderate to severe RA and did not respond adequately to the drug methotrexate. Patients were placed at random in groups that received either weekly injections of Orencia with a single IV loading dose or IV Orencia with methotrexate. After six months, 69.8% of those receiving injections and 65% of those on IV were showing improvements.
“These findings are significant because they demonstrate that subcutaneous Orencia may provide an additional administration option for patients and physicians,” lead study author and Stanford University medical professor Mark Genovese said. “It is important for patients and physicians to have treatment options when managing RA.”